SolGel Technologies (SLGL)
(Delayed Data from NSDQ)
$0.75 USD
+0.05 (6.78%)
Updated Sep 20, 2024 11:30 AM ET
1-Strong Buy of 5 1
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Sol-Gel Technologies Ltd. [SLGL]
Reports for Purchase
Showing records 1 - 20 ( 50 total )
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
1Q24 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Regional Licensing Deal Inked; Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
SGT-610 Showcased; Pivotal Trial Starts Patient Screening; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Revenue Miss; Slow Road Ahead; 3Q23 Financial Results; Lowering PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Revenue Miss, Slower-Than-Anticipated Trajectory; Lowering PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Market Traction Poised to Accelerate; Canadian Partnership; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Top-Line Beat, Bottom-Line Miss; Pipeline Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Pipeline Developments; Balance Sheet Solidity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Patidegib In-Licensed for Gorlin Syndrome; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Twyneo and Epsolay Starting Slowly; 3Q22 Financials; Reducing PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Solid Expense Control; 2Q22 Financials; Raising PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Product Launches Under Way; 1Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Epsolay Receives FDA Approval; Raising PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Twyneo Commercial Availability; 2021 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Facility Inspection Scheduled; Epsolay Approval Near-Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Generics Portfolio Divested; 3Q21 Financials; Reducing PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Top- and Bottom-Line Miss; 2Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
First FDA Approval Notched as Twyneo Gets Green Light; Raising PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Sol-Gel Technologies Ltd.
Industry: Medical - Generic Drugs
Marquee Partnership Inked; Pipeline Focus; Modulating PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R